Predictix® is designed to help clinicians choose the antidepressant best suited to the metabolizer profile of patients with Major Depressive Disorder (MDD).

Indeed, the choice of therapeutic molecule represents a major challenge to successful treatment. 

In partnership with Taliaz, the Cerba laboratory, a European leader in innovation in medical biology, offers the Predictix® test, which assesses the probability of response to a range of antidepressant molecules based on :
- identification of the patient's genotypes using the new MassARRAY® technology (Agena Bioscience).
- patient clinical and demographic data, assessed by CE-certified artificial intelligence (AI) algorithms.

For each patient, a personalized report is sent to the prescribing physician, providing details and bibliographic data.

Predictix®

An approach combining AI, clinical and demographic data and Pharmacogenetics

  
To find out more, read the Predictix® NewsLetter

Access to the catalog Prescription forms and patient questionnaire

Please do not hesitate to contact us 
Yours faithfully 
 

Cerba International Customer Relations Department
intgb@lab-cerba.com